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Abstract Hypertension (high blood pressure) is a major
public health problem affecting more than a billion people
worldwide with complications, including stroke, heart
failure and kidney failure. The regulation of blood pressure
is multifactorial reflecting genetic susceptibility, in utero
environment and external factors such as obesity and salt
intake. In keeping with Arthur Guyton’s hypothesis, the
kidney plays a key role in blood pressure control and data
from clinical studies; physiology and genetics have shown
that hypertension is driven a failure of the kidney to excrete
excess salt at normal levels of blood pressure. There is a
number of rare Mendelian blood pressure syndromes,
which have shed light on the molecular mechanisms
involved in dysregulated ion transport in the distal kidney.
One in particular is Familial hyperkalemic hypertension
(FHHt), an autosomal dominant monogenic form of
hypertension characterised by high blood pressure, hyper-
kalemia, hyperchloremic metabolic acidosis, and
hypercalciuria. The clinical signs of FHHt are treated by
low doses of thiazide diuretic, and it mirrors Gitelman
syndrome which features the inverse phenotype of
hypotension, hypokalemic metabolic alkalosis, and
hypocalciuria. Gitelman syndrome is caused by loss of
function mutations in the thiazide-sensitive Na/Cl
cotransporter (NCC); however, FHHt patients do not have
mutations in the SCL12A3 locus encoding NCC. Instead,
mutations have been identified in genes that have revealed
a key signalling pathway that regulates NCC and several
other key transporters and ion channels in the kidney that
are critical for BP regulation. This is the WNK kinase
signalling pathway that is the subject of this review.
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Introduction
Hypertension (high blood pressure) is a major public health
problem affecting more than a billion people worldwide
with complications, including stroke, heart failure and
kidney failure [1]. The regulation of blood pressure (BP) is
multifactorial reflecting genetic susceptibility, in utero
environment and external factors such as obesity and salt
intake. In keeping with Arthur Guyton’s hypothesis, the
kidney plays a key role in blood pressure control [2] and
data from clinical studies; physiology and genetics have
shown that hypertension is driven by a failure of the kidney
to excrete excess salt at normal levels of blood pressure.
There is a number of rare Mendelian blood pressure syn-
dromes (Fig. 1), which have shed light on the molecular
mechanisms involved in dysregulated ion transport in the
distal kidney. One in particular is Familial hyperkalemic
hypertension (FHHt), a monogenic form of hypertension
characterised by high blood pressure, hyperkalemia,
hyperchloremic metabolic acidosis, and hypercalciuria [3].
The clinical signs of FHHt are treated by low doses of
thiazide diuretics [4], and it mirrors to an extent Gitelman
syndrome [5] which features the inverse phenotype of
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hypotension, hypokalemic metabolic alkalosis, hypomag-
nesemia, and hypocalciuria. However, it is worth
emphasising that FHHt patients are typically normomag-
nesemic and Gitelman patients are usually normotensive.
Gitelman syndrome is caused by loss of function mutations
in the thiazide-sensitive Na/Cl cotransporter (NCC), but
FHHt patients do not have mutations in the SCL12A3 locus
encoding NCC. Instead, mutations have been identified in
genes that have revealed a key signalling pathway that
regulates NCC and several other key transporters and ion
channels in the kidney that are critical for BP regulation.
This is the WNK kinase signalling pathway that is the
subject of this review.
WNK kinases
The WNK kinases are a family of four evolutionarily
conserved serine–threonine kinases (WNK1, WNK2,
WNK3 and WNK4) that share[85% homology over their
kinase domains and form a distinct branch of the phylo-
genetic tree of the human kinome (Fig. 2) [6]. However,
unlike other kinases they use a catalytic Lys residue
downstream from the usual site deep in the kinase core
(kinase subdomain I). Hence, the term WNK (With No Lys
(K)) referring to the absence of the usual N-terminal
canonical kinase Lys residue for docking ATP and phos-
phoryl transfer (e.g. Lys72 in Protein Kinase A). This shift
to a more superficial and distal glycine-rich loop for their
canonical Lys has allowed WNKs to adapt their function
and roles by acquiring an important sensitivity to chloride
[7] (see ‘‘Intracellular Cl- modulates activity of WNK
kinases’’). Overlap of the ‘chloride sensor’ in WNKs with
the proximal canonical Lys residue explains the use of a
distal Lys residue in the WNKs for their kinase activity
(e.g. Lys233 in WNK1). This unique feature has lead to
changes to WNK tertiary structure recently exploited in the
development of a highly WNK-selective inhibitor (see
‘‘WNK/SPAK/OSR as a druggable signalling pathway’’).
Another key property of theWNKkinases directly related
to their ‘chloride sensor’ behaviour is inactive and active
forms; with phosphorylation stabilising the active state [7].
Chloride anions inhibit this autophosphorylation, which
explains howWNKkinase activity can respond to changes in
intracellular chloride concentration [Cl-] and tonicity [8, 9].
This low Cl- activation occurs rapidly (in\0.5 min) and
involves phosphorylation of Ser382 in the T-loop of WNK1,
which is conserved across all theWNKs [10]. The discovery
of the ‘chloride sensor’ is recent, but follows long-standing
speculation about the existence of a chloride-sensing regu-
latory kinase to explain the behaviour of Na? and K? cation
cotransporters (NKCCs) in determining [Cl-] [11]. The need
for this level of control reflects the importance of intracel-
lular chloride in regulating cell volume itself, neuronal
function and cell growth [12]. Recent crystallographic data
has identified an LGL motif dubbed the ‘chloride sensor’ in
WNK1 that confers chloride sensitivity by blocking the
autophosphorylation of the T-loop [7]. This discovery of the
chloride-sensing capacity of the WNKs has confirmed them
as the ‘missing-link’ kinase in chloride regulation. It seems
likely that WNK1 played a pivotal evolutionary role in
controlling cell volume in single cells, although the only
unicellular organism with a WNK1 orthologue identified so
far is the dimorphic fungusPenicilliummarneffei (GenBank:
Fig. 1 Diagram of the human
nephron showing the locations
where the main Mendelian
syndromes affecting BP operate
and the molecular mechanisms
involved. The Na?, K?-ATPase
is expressed along the nephron
but due to space limitations is
only shown in the CD.
Abbreviations of nephron
segments: CD collecting duct,
DCT distal convoluted tubule,
TAL thick ascending limb
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KFX50394.1). The development of closed cardiovascular
systems in larger complex metazoan organisms may have
necessitated the refinement of its volume regulatory function
with gene duplication deriving later WNKs (WNK2–4).
What is clear is that the WNKs now have a very diverse
biology and a central role in the control of blood pressure.
Inherited hypertension and WNK signalling
Four different genes have been implicated in FHHt
(Table 1; Fig. 1) and two of them encode for WNK kina-
ses: WNK1 and WNK4. The WNK1 sequence was first
identified in 2000 from a rat brain cDNA library [13], but
its function was unclear until intronic mutations were
identified in the WNK1 gene in human pedigrees segre-
gating the FHHt phenotype. These mutations were
associated with elevated levels of WNK1 messenger RNA
in peripheral monocytes from the affected patients and
further missense mutations were identified in the ortholo-
gous WNK4 gene of other unrelated pedigrees [14]. The
other two FHHt genes, CUL3 (Cullin3) and KLHL3 (Kelch-
like 3), which were discovered through a whole exome
sequencing strategy, regulate WNK kinase levels in the
cell. Together Cullin3 and KLHL3 form a Cullin-RING
type E3 ubiquitin ligase complex that targets WNK kinases
Fig. 2 Zoomed section of the
human kinome to show the
close evolutionary proximity of
WNKs and OSR1/SAPK From
reference [6] with permission
Table 1 FHHt mutations and their effects on the affected genes
Gene Effect Result Effect on the
encoded protein
References
WNK1 Deletion of intron I : WNK1 expression : L-WNK1
expression
[14, 25]
WNK4 Missense mutation in the
acidic motif
: WNK4 expression due to disruption in the KLHL3
recognition site
: WNK4 [14, 15, 17, 81]
WNK4 R1185C mutation in the
C-terminal domain
Disrupts a regulatory mechanism involving calmodulin
binding and SGK1 phosphorylation sites
Unknown [26, 27]
KLHL3 Missense mutations in the
BTB or BACK domain
Disruption of the CUL3–KLHL3 interaction : WNK1
: WNK4
: WNK3
[15, 17, 18, 81, 82]
Missense mutations in the
Kelch propeller blades
Disruption of the substrate (WNK) binding : WNK1
: WNK4
: WNK3
CUL3 Exon 9 deletion Increased KLHL3 ubiquitination and degradation ;KLHL3
: WNK1
: WNK4
: WNK3
[15, 17, 86]
Altered CUL3 flexibility leading to CUL3 auto-degradation
and prevention of WNK ubiquitination
[16]
: indicates increase, ; indicates decrease
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for ubiquitination to promote their proteasomal degrada-
tion. Cullin3 is a scaffold protein that coordinates the
enzymatic and substrate binding activities of the ubiquitin
E3 ligase. KLHL3 is the substrate receptor protein that
recruits WNKs to the E3 ligase complex to present them
for ubiquitination. Once ubiquitinated, WNKs are degraded
by the 26S proteasome. Mutations in CUL3 cause a dom-
inantly inherited severe form of FHHt [15, 16]. It has been
suggested that these mutations may increase ubiquitination
and degradation of KLHL3, preventing WNK recruitment
to the ligase complex, and thus indirectly abolishing
WNK4 degradation [17, 18]. However, other work has
suggested that the mutations affect the molecular flexibility
of Cullin3 and lead to its auto-degradation by auto-ubiq-
uitination, without affecting KLHL3 levels [16] (‘‘CUL3-
KLHL3 as upstream regulators of WNK kinases’’). In
contrast to CUL3mutations, mutations in KLHL3 can result
in either a dominant or recessive form of FHHt [18].
KLHL3 interacts directly with the CUL3 substrate (WNK
in this case) and some recessive KLHL3 mutations directly
inhibit this interaction. This prevents WNK ubiquitination
and degradation further supporting the notion that elevated
WNK levels lead to hypertension [17].
The association of mutations in the WNK kinases with
FHHt suggested that an entirely novel pathway existed,
connecting WNK kinases with renal electrolyte home-
ostasis and blood pressure. The last 15 years has been spent
unravelling the molecular basis and complexity of this
pathway. A crucial feature is the ability of WNK signalling
to coordinate two competitive aldosterone-controlled pro-
cesses: NaCl reabsorption (from the urine to the blood) and
K? secretion (from the blood to the urine) in the distal
nephron to regulate blood pressure and maintain electrolyte
homeostasis [19]. Work from groups in Yale and Oregon
showed that this was achieved by WNKs regulating the
phosphorylation and activities of cation-chloride cotrans-
porters (CCCs), including NCC (in the DCT, distal
convoluted tubule), KCC4 and NKCC2 (in the TAL, thick
ascending limb) [20–22] and the ROMK channel [23], and
the epithelial Na? channel ENaC in the distal tubule and
collecting duct [24]. The FHHt mutations reported in
WNK1 [14, 25] are large deletions of the first intron that
result in an increased expression of WNK1 message,
whereas those in WNK4 are missense mutations that are
clustered in the highly conserved acidic motif [26]. To
date, only one of the WNK4 mutations has been reported
outside of the acid motif in the C-terminal domain [27].
Increased expression of WNK proteins alters the quan-
titative effects that they have on distal ion transport in the
kidney, and is the common molecular driver for the FHHt
phenotype. Since the discovery of the WNK kinases, a
number of groups have focused on the regulation of NCC
and other transporters by WNK proteins including WNK1
and WNK4. Here, we review the current understanding of
the molecular signalling pathways used by WNKs, which
regulate ion transport in the distal nephron of the kidney.
Renal ion transporters such as NCC and NKCC2 are
driven by the favourable Na? gradient established by pri-
mary active transport through the Na?,K?- ATPase (Na?-
and K?-dependent adenosine triphosphatase). NCC,
NKCC1 and NKCC2 are the Na? driven Cl- importing
transporters that contrast with a more recently discovered
family of K? driven Cl- exporting transporters (KCC1–4)
[28]. All these transporters are regulated by WNK kinases.
In most cell types, the intracellular Cl- concentration
([Cl-]i) is tightly regulated by influx of Cl
- through NCCs
and an efflux of Cl- via the KCCs. The [Cl-]i is crucial for
core physiological processes, such as transepithelial solute
and water transport, volume regulation and neuronal
excitability in neurons [29]. Cell shrinkage or a decrease in
intracellular ([Cl-]i), or both, triggers the phosphorylation
of NCC, NKCCs and KCCs, which leads to the activation
of NCC and NKCCs and inactivation of KCCs, respec-
tively. The converse is true when the [Cl-]i is high or when
the cell swells, leading to a dephosphorylation of these two
sets of transporters and inactivating NCCs, and activating
KCCs. Thus, the same signals achieve a tight coordination
of Cl- influx and efflux via the inverse regulation of Na?
and K? driven Cl- transport by a common Cl--sensitive
kinase in the form of the WNKs. The fact that this efficient
phospho-regulatory mechanism is highly conserved from
worms to humans shows how important it is for cell
function and survival [30].
Mechanisms of WNK activation, and their
downstream targets
A combination of molecular genetics [14, 31, 32], physi-
ology [19, 20, 33, 34] and biochemistry [35] has shown that
the components of the signalling complex downstream of
WNK kinases are serine–threonine protein kinases that
share high sequence homology. The targets are SPAK
(STE20/SPS1-related proline–alanine-rich protein kinase)
and OSR1 (or OXSR1, oxidative stress responsive 1) that
are closely related members of the STE-20 branch of the
kinome (Fig. 2). The kinase domains of SPAK and OSR1
show around 89% homology, whereas at the whole protein
level, the degree of homology is approximately 67%. A
major difference between SPAK and OSR1 is the presence
of a proline- and alanine-rich region (PAPA box) in the
N-terminal domain of SPAK which is upstream of the
catalytic domain [36]. There are three different isoforms of
SPAK with the full-length isoform (FL-SPAK) being
expressed ubiquitously with higher expression in the brain,
heart, and testis [37, 38]. SPAK2, the second isoform, lacks
M. Murthy et al.
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the N-terminal PAPA box and a part of the kinase domain,
and is also expressed ubiquitously. Kidney-specific SPAK
(KS-SPAK) is the third isoform which is expressed mainly
in the kidney, as the name suggests. Immunofluorescence
studies showed that the FL-SPAK co-localized with NCC
at the DCT, whereas SPAK2 and KS-SPAK are more
abundant in the TAL, the site of NKCC2 expression [39].
WNKs phosphorylate and activate SPAK and OSR1,
which in turn bring about the coordinated phosphorylation
of NCC and NKCC2 in the DCT and TAL of the nephron,
respectively (Fig. 3). Thus, the SPAK/OSR1 kinases con-
tinue the phosphorylation cascade that connects the WNKs
and the CCCs. Activation of SPAK and OSR1 takes place
in an analogous manner to WNK autophosphorylation with
WNKs phosphorylating a conserved Thr residue (SPAK
Thr233, OSR1 Thr185; Fig. 3) within the SPAK/OSR1 cat-
alytic T-loop motif [19]. The Ser383 is also phosphorylated
in SPAK although its functional consequences are unclear
[40]. Furthermore, in vitro assays have shown that mouse
protein-25 (MO25), which functions as a scaffold, interacts
with both SPAK and OSR1, and enhances their catalytic
activities [41]. In addition to the catalytic domain, the
SPAK/OSR1 have a conserved C-terminal domain (CCT)
which is important for docking with the RFXV/I peptide
motif in the N-terminus of CCCs such as NCC and NKCCs
[9, 42] (Fig. 3). The CCT domain also binds to the RFXV/I
peptide motif in WNK kinases bringing them into close
proximity with SPAK and OSR1 to activate them. This
interaction between the CCT docking domain and WNK
kinases plays a major role in blood pressure regulation.
OSR1 has been shown to have a highly conserved Leu
residue that lies in the base of a deep hydrophobic pocket,
and this forms the crucial hydrophobic contacts with the
Phe residue of the RFXI motif [43]. Consistent with this in
a mouse model carrying a single point mutation
(Leu502Ala), the interaction between the docking domain
of SPAK and the RFXV motifs on its WNK activators or
ion cotransporters is abolished. The mouse also showed
reduced phosphorylation and levels of NCC/NKCC2,
resulting in a *20 mmHg reduction in BP [44].
The realization that both the kinase and the CCT
domains are crucial for SPAK/OSR1 function suggested
that they could serve as a potential drug targets to screen
for novel antihypertensive compounds. The potential for
WNK/SPAK/OSR1 to be a druggable signalling pathway is
discussed below (‘‘WNK/SPAK/OSR as a druggable sig-
nalling pathway’’).
SPAK kinase is crucial for the phosphorylation
and activity of NCC
The N-terminal tail of NCC has the minimum SPAK
binding motif, RFXV/I which has a docking interaction
with the C-terminal domains of SPAK/OSR1, which in turn
phosphorylates NCC on three highly conserved residues,
Thr46, Thr55, and Thr60 (human amino acid numbering;
Fig. 3). It has been reported that human NCC can also be
Fig. 3 The domain structure of
SPAK and the phosphorylation
target sites on NCC, NKCC1
and NKCC2. OSR1 differs from
SPAK in lacking the P/A rich
(PAPA) domain
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phosphorylated on its Ser91 residue during Cl- depletion by
an as yet unidentified kinase [45]. Phosphorylation of Ser71
(Ser73 in humans) is also altered in SPAK-deficient mice,
suggesting that the kinase is essential for the phosphory-
lation of this site [46]. Although both SPAK/OSR1 kinases
are able to phosphorylate NCC in vitro, SPAK is essential
for the NCC phosphorylation and activation in vivo.
A number of mouse models have been generated
(Table 2) to characterize the SPAK kinase function: (1) a
global knockout which inactivates the full-length and
truncated forms of SPAK [39, 44, 46]; (2) a kinase ablating
knock-in mutant (SPAK T243A/243A) where a missense
mutation in the T-loop of SPAK prevents its activation by
WNKs, and (3) a knock-in mutant (SPAKL502A/L502A)
which is SPAK CCT domain defective and leading to
markedly reduced SPAK activity and phosphorylation of
CCCs such as NCC and NKCC2 [44]. In all the models,
NCC phosphorylation is markedly reduced, and both the
SPAKT243A/T243A and SPAKL502A/L502A knock-in mutants
display features of Gitelman syndrome.
Genetic inactivation of OSR1 causes embryonic lethal-
ity due to defective angiogenesis and cardiovascular
development [47, 48] (Table 2). The targeted inactivation
of OSR1 in the distal nephron results in hypokalemia and a
mild volume depletion due to the reduced expression,
phosphorylation and activity of NKCC2, clinical symptoms
similar to Bartter syndrome [47]. These mice show an
increased NCC and phosphoNCC expression which
probably compensates for the decreased NKCC2 activity.
The expression and phosphorylation of NKCC2 was
reduced in both SPAKT243A/T243A and SPAKL502A/L502A
knock-in mutants, but there was an increase in the SPAK
knockout mice. This difference might be due to the inhi-
bitory effect of shorter SPAK isoforms on NKCC2, which
are present in the knock-in models but not in the knockout
mice. These results show that SPAK activates NCC, and
that OSR1 cannot fully compensate for its absence. A
recent double knockout mouse (lacking both SPAK and
OSR1 activity) supports this, but also showed that there
was substantial phoshoNKCC2 still present in the medulla
suggesting another unrecognised kinase is important for
NKCC2 phosphorylation [49].
SPAK as a blood pressure risk allele for essential
hypertension
Essential hypertension (EH) unlike the rare single gene
Mendelian forms such as FHHt is caused by the effects of
tens of genes whose impact is modified by gene–gene
interactions and epigenesis [50, 51]. In fact, the genes
coding for proteins in the WNK signalling cascade do not
feature in the genetic architecture of EH. The gene
encoding SPAK, STK39, is a singular exception. It covers
300 kb of chromosome 2 and was first identified as a
hypertension susceptibility locus in a Genome-Wide
Table 2 Mouse models in which SPAK-OSR1 have been genetically modified
Gene Genetic modification Effect on blood
pressure
Expression and
activity of NCC
Phenotype References
SPAK SPAK-/- ; with a Na?
depleted diet
;; Hypokalemia with K? depleted diet [39]
SPAK-/- ND ;; Vasopressin induced NCC phosphorylation
No NKCC2 phosphorylation
[125]
SPAK-/- ND ND Decreased NKCC2 mediated Na? reabsorption [126]
SPAK-/- ; ;; Gitelman syndrome [46]
SPAK-/- ND ND Na absorption in the TAL blunted, vasopressin
stimulation of NKCC2 intact
[127]
SPAKT243A/T243A ; ;; Gitelman syndrome [38]
SPAKL502A/L502A ; ;; Gitelman syndrome [44]
OSR1 OSR1-/- NA NA Embryonically lethal [48]
Kidney-specific inactivation (KSP-
OSR1-/-)
Normal :: Bartter syndrome [47]
OSR1?/- ; :: Bartter syndrome [47]
SPAK/
OSR1
SPAK-/-/OSR1flox/flox/Pax8-rtTA?/Cre?
double knockout (DKO)
; ;; pNKCC2 levels still high
Compensatory changes in NKCC2 and NCC
[49]
: indicates increase, ; indicates decrease and number of up or down arrows the size of the effect
NA not applicable, ND not determined
M. Murthy et al.
123
association study of the Pennsylvania Amish [52]. It was
replicated in several other Amish and non-Amish Cau-
casian cohorts. The blood pressure effect size of the
strongest STK39 alleles was up to 3 mmHg in the Amish,
but smaller and less consistent across the other groups.
Some of the alleles were also relatively frequent in these
populations at[9%. However, the association has not been
replicated in other studies notably those using a black
American cohort [53] and in the Chinese Han. Although
one study in Han Chinese found association in obese not in
non-obese children [54], suggesting the allele is actually an
obesity risk factor. A more recent meta-analysis of almost
22,000 hypertensives has confirmed the association in
Europeans and East Asians but not Black American
hypertensives [55]. So, it remains unclear whether the
association of BP with STK39 alleles is a false positive one
or is population specific. The latter is suggested by a study
in Northeastern Chinese Han people indicating that the
association in the Han is regionally distinct and involve the
interplay of several STK39 alleles (rs6749447, rs35929607
and rs3754777) [56].
While the influence of STK39 genetic variation on blood
pressure is not clear, genetic variation in its phosphoryla-
tion target, NCC, is important. Over 100 mutations in the
SCL21A3 gene, which encodes for NCC, have been doc-
umented in patients with Gitelman syndrome. Amongst the
missense mutations within the coding region one is highly
relevant to WNK signalling: T60M (homologous to mouse
T58). It inactivates one of the key Thr residues for NCC
activation and is a frequent mutation in South Asia [57]
(Fig. 3). Mice homozygous for this mutation recapitulate
the Gitelman phenotype very closely [58].
WNKs as upstream regulators of SPAK in NCC
activation
WNK1, WNK3 and WNK4 are expressed in the kidney,
and the WNK1 gene produces two isoforms, a long isoform
called the L-WNK1 and a shorter, kidney-specific WNK1
(KS-WNK1). The L-WNK1 contains the entire kinase
domain and is expressed ubiquitously, whereas the KS-
WNK1 is devoid of the kinase activity, and is expressed
only in the distal nephron. Initial studies on the effect of
L-WNK1 on NCC in in vitro systems such as cell lines or
Xenopus oocytes showed that this form of WNK1 had no
effect on NCC expression or activity, but it abolished the
inhibitory effect of WNK4 on NCC [59, 60]. However,
L-WNK1 activated SPAK by phosphorylation, which
indicated that it could activate NCC in a SPAK-dependent
manner [45, 61]. The relevance of these pathways in vivo
could not be tested because the L-WNK1 knockout models
were embryonically lethal with developmental defects in
the cardiovascular system, similar to those observed in
OSR1-deficient embryos (Table 2) [48, 62, 63]. However,
a mouse model with human WNK1 mutations (large dele-
tions of the first intron of the WNK1 gene) fully
recapitulated the FHHt phenotype showing an increase in
L-WNK1 specifically in the DCT and CNT, with no
changes in KS-WNK1 expression. Increased NCC
expression and phosphorylation was also noted, and these
WNK1?/FHHt mice displayed an increased level of SPAK
phosphorylation in the DCT, and more abundant SPAK
levels at the apical membrane of the DCT when compared
with wild-type mice. The FHHt phenotype was maintained
in these mice even in the absence of WNK4. Thus, this
study indicated a L-WNK1/SPAK pathway for NCC acti-
vation [24, 25].
WNK3 also activates NCC by a kinase- and SPAK-
dependent mechanism, similar to L-WNK1 [64, 65].
WNK3 does not activate NCC in the absence of its kinase
activity, and interestingly, the kinase dead WNK3 mutant
is a potent inhibitor of the cotransporter. This shows that in
the absence of activation, WNKs can have an opposite
effect (or dominant-negative effect) on their target protein
[65, 66]. WNK3 knockout mice have a very mild pheno-
type, and show a slight decrease in blood pressure during
salt depletion. Their kidneys have an increased expression
of L-WNK1, where it probably compensates for the
absence of WNK3, and thus maintains NCC phosphoryla-
tion [67].
The effect of WNK4 on NCC is paradoxical, with both
in vitro and in vivo studies showing that WNK4 can behave
as an inhibitor as well as an activator of NCC [68].
Although these discrepancies in the literature now have to
be viewed in the knowledge that [Cl-] was a potential
unrecognised confounder in these reports (see ‘‘Intracel-
lular Cl- modulates activity of WNK kinases’’). Most
in vitro studies have shown that WNK4 inhibits NCC
activity by abolishing the effect of WNK1 or WNK3 on
NCC [69]. In vitro studies involving Xenopus oocytes
showed that angiotensin II (AngII) signalling increased
NCC activity by abolishing the inhibition by WNK4 of the
cotransporter, and this effect required AngII, its receptor
AT1R, and WNK4, and was prevented by the AT1R
antagonist losartan. The effect of AngII on NCC was
dependent on SPAK kinase because a dominant-negative
SPAK or the removal of the SPAK binding motif in NCC
prevented activation of NCC by AngII signalling, and this
was also reported in the mpkDCT cell expression system
[70]. In vivo studies in mice have shown that WNK4 is
essential for basal phosphorylation and activation of NCC
through its interaction with SPAK. WNK4 inactivation
resulted in a significant reduction in NCC expression and
activity, and this is associated with hypokalemia and
metabolic alkalosis. The absence of WNK4 also abolished
WNK signalling pathways in blood pressure regulation
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the stimulatory effect of AngII on phosphorylation of
SPAK and NCC [71]. The converse of this, overexpression
of WNK4 in a transgenic mouse model, was consistent in
producing a Gitelman-like phenotype [71].
Intracellular Cl2 modulates activity of WNK
kinases
As discussed in ‘‘WNK kinases’’ in this review, crystallo-
graphic studies of WNK1 in its inactive state, and in the
presence of Cl- revealed that the anion binds directly to the
catalytic domain, which could be the basis for the unique
positioning of the catalytic lysine residue. This work by
Piala et al. [7] showed that WNK1 fragments have a
putative chloride-binding pocket formed by Leu369 and
Leu371 in the DLG motif (Fig. 4), and the binding of Cl-
prevents WNK1 autophosphorylation. Therefore, the
higher the intracellular [Cl-], the lower the level of
autophosphorylation and hence reciprocal activation of
WNK1. The effect of WNK4 on NCC within whole cells is
also modulated by intracellular [Cl-]. A recent study in
Xenopus oocytes has shown that WNK4 has an inhibitory
effect on NCC in normal solutions, whereas when exposed
to low [Cl-]/hypotonic conditions, it activates the NCC
and thus promotes Cl- efflux and a decrease in intracellular
[Cl-] [68]. Mutating Leu322 (Leu369 in L-WNK1) resulted
in the constitutive phosphorylation and activation of
WNK4, and thus stimulation of NCC by WNK4 in control
conditions. Thus, intracellular [Cl-] modulates the inhibi-
tory versus activating effect of WNKs on NCC [68] and the
discrepancies previously reported in vitro (see ‘‘WNKs as
upstream regulators of SPAK in NCC activation’’) proba-
bly reflect unrecognised differences in intracellular [Cl-].
Work by Terker et al. [72] has further shown that although
the Cl- binding pocket is conserved by all the WNK
kinases, it is WNK4 that has the highest sensitivity to
[Cl-]i. This is especially striking over the physiological
range thought to exist within a DCT cell (10–60 mM)
(Fig. 4) [73].
Extracellular K1 as the ultimate regulator
of WNK/SPAK/NCC pathway
Recent work from the Ellison group has provided com-
pelling evidence that the activity of the WNK/SPAK
signalling pathway in the DCT is regulated by the plasma
K? or more precisely the concentration of K? in the per-
itubular fluid [72]. It does this through its effects on the
membrane potential of DCT cells (Fig. 5). Using HEK
cells expressing NCC as a model for the DCT cell, they
showed that levels of phosphoNCC and phosphoSPAK
were directly affected by the extracellular K? with a low
K? increasing the levels of both proteins. This effect of K?
was inhibited by both Rb? and Ba2? (to block K channels).
Since Kir 4.1(KCNJ10; Fig. 5) is the predominant K
channel in the DCT, they further showed that if mutants of
this channel (which cause a Gitelman-like syndrome in
humans) were expressed in the HEK cells it both depo-
larized them and reduced phosphoNCC levels.
A previous model for the DCT that incorporates a
basolateral KCl cotransporter and a CIC channel predicted
that depolarization would reduce intracellular [Cl-] [74],
and they were able to demonstrate this in their HEK model
using a chloride-sensitive fluorescent dye. Discovery of a
chloride sensor in WNKs (see ‘‘WNK kinases’’ and ‘‘In-
tracellular Cl- modulates activity of WNK kinases’’)
provides an elegant explanation for coupling of extracel-
lular [K?] to NCC function through alteration in
Fig. 4 Shows the relation
between the phosphorylation
state of SPAK in vitro and the
concentration of Cl-, [Cl-]. The
latter is sensed through the
chloride sensor motif on the
WNKs that directly inhibits
WNK kinase activity. Over the
physiological range (highlighted
in pink) WNK4 shows the
greatest sensitivity to [Cl-]. KD
here means kinase domain From
reference [66] with permission
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intracellular [Cl-]. The Ellison group tested this directly by
expressing WNKs with mutated chloride sensor motifs to
render them insensitive to intracellular [Cl-] [72]. The
HEK cells no longer responded to changes in extracellular
[K?] and showed increased levels of phosphoWNK con-
sistent with unrestricted WNK autophosphorylation. They
also showed that this derepressive effect of chloride sensor
mutation was much larger for WNK4 than other WNKs
[72]. This is in keeping with the in vitro sensitivity of the
WNK4 to [Cl-] (Fig. 4) and probably explains why WNK4
has become the most important WNK for DCT function.
The model proposed by Ellison has been partly verified
using a more physiological approach using perfused mouse
kidney and ex vivo slices [73]. Once again low extracel-
lular [K?] causes rapid phosphorylation of NCC through
WNK/SPAK/OSR1 pathway activation. Using microper-
fused DCT tubules, the authors were also able to show that
membrane potential changes at the luminal surface were
most important. However, in contrast to Ellison they found
that the dephosphorylation that occurs with high extracel-
lular [K?] was not dependent on Cl-. This suggests that the
dephosphorylation is regulated by so far undisclosed sig-
nalling molecules that are not part of WNK/SPAK
signalling.
CUL3–KLHL3 as upstream regulators of WNK
kinases
While mutations in WNK1 and WNK4 are known to cause
FHHt, only about 13% of the affected pedigrees show
mutations in these two genes [75]. As discussed in the
introduction, recent studies have reported that mutations in
CUL3 and KLHL3 also cause FHHt [15, 18]. CUL3
belongs to a protein family that consists of seven Cullins
(Cul1, -2, -3, -4a, -4b, 5, and -7), which are all
involved in the degradation of intracellular proteins by
forming ubiquitin E3 ligases [76, 77]. These so-called
Cullin-RING ligases share a common architecture, in
which the Cullins act as the scaffold for nucleation of other
E3 ligase subunits (Fig. 6). Ubiquitin E3 ligases are the
final enzymes in an enzymatic cascade that leads to the
ubiquitination of target proteins. Prior to ligation by E3s,
ubiquitin is activated by an E1 activating enzyme and
transferred to E2 conjugating enzymes [78]. The E3s are
the most critical step, as they provide substrate specificity
and are also often subject to regulation. The Cullins
themselves are 80–100 kDa in size and structurally consist
of an elongated N-terminal domain and a globular C-ter-
minal domain. The very N-terminus of the Cullin binds to
substrate adaptor and receptor proteins to recruit the sub-
strate for ubiquitination. The E3 ligase activity resides in
the C-terminus and is mediated by a small RING finger
protein, either Rbx1 or Rbx2, which stably interacts with
the Cullin C-terminus and recruits ubiquitin-charged E2
enzymes to transfer ubiquitin onto the substrate protein
[79] (Fig. 6). Because of their modular setup, the Cullin-
RING E3s are the largest class of ubiquitin E3 ligases in
mammals.
Most of the seven Cullin proteins interact with their own
unique set of substrate adaptor and receptor subunits. In the
case of Cullin3, these are the so-called broad com-
plex/tramtrack/bric-a-brac (BTB) proteins [76], which are
characterised by BTB domains that mediate the interaction
with CUL3. One subclass of BTB proteins are the Kelch-
like (KLHL) proteins, a family of more than 40 Cullin3
substrate adaptors/receptors, which includes KLHL3.
Kelch proteins connect the substrates to the Cullin3-RING
ubiquitin ligase through their Kelch domains (Fig. 6) [80].
Kelch domains form beta propellers and X-ray crystal
structures of the KLHL3 Kelch domains bound to WNK
peptide revealed multiple sites of interaction, which
involve residues that are mutated in FHHt patients in either
WNK4 or KLHL3 [16, 17]. Indeed, mutant WNK4 proteins
carrying mutations within the so-called acidic motif cannot
be immunoprecipitated with KLHL3 in vitro (Ref. [17]).
Mutations in both CUL3 and KLHL3 are predicted to
impair the degradation of WNK kinases. The majority of
Fig. 5 Diagram showing the
hypothetical model for
regulation of NCC
phosphorylation in the DCT
cell, and hence the level of
transcellular NaCl flux. Activity
in the WNK/SPAK/NCC
pathway is directly regulated
through the extracellular [K?],
causing parallel changes to
intracellular [Cl-] and WNK4
kinase activity
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FHHt-linked KLHL3 mutations either disrupt binding to
CUL3 or WNKs (see Fig. 6) to prevent the formation of an
active E3 ligase. FHHt-causing mutations in KLHL3
directly block their interaction with WNK4, which reduces
its ubiquitination and levels in both mammalian cells lines
and kidney lysates from a mouse model expressing a typ-
ical acid motif FHHt mutation (WNK4D561A [81]). This
provides an elegant molecular explanation for how these
mutations stabilise WNKs by preventing their degradation
by ubiquitination and removal by the proteasome [17]. The
findings that these mutations also cause FHHt strongly
support the idea that both WNK1 and WNK4 activate NCC
[15, 18, 82]. Further, knock-in mice with FHHt-like
mutations in KLHL3 [R528H] have been reported to have
an increased abundance of WNK1 and WNK4 proteins and
increased NCC activity. In this model, Arg528 that makes
critical interactions with the WNK4 degron motif is
mutated, and the mice displayed a marked increase in
blood pressure [83]. This presumably caused activation of
the WNK/SPAK/OSR1 kinase cascade and hypertension
through excess activity of the WNK/SPAK/NCC pathway.
Mutations in both CUL3 and KLHL3 are predicted to
impair the degradation of WNK kinases. In fact, most
FHHt-linked KLHL3 mutations either disrupt binding to
CUL3, which stops assembly of the E3 complex, or to
WNKs, which prevents WNK recruitment to the E3
(Fig. 6). Both mechanisms ultimately result in a loss of
WNK ubiquitylation and degradation [17]. The findings
that these mutations also cause FHHt strongly support the
idea that both WNK1 and WNK4 activate NCC
[15, 19, 73]. Further, knock-in mice with FHHt-like
mutations in KLHL3 [R528H] have been reported to have
an increased abundance of WNK4 proteins and increased
NCC activity. In this model, Arg528 that makes critical
interactions with the WNK4 degron motif is mutated, and
the mice displayed a marked increase in blood pressure and
increased abundance of WNK1 and WNK4 isoforms [74].
Similarly, transgenic heterozygous mice expressing a ver-
sion of WNK4 that carried a familial FHHt mutation in the
KLHL3 binding site (D561A/?) displayed increased
WNK4 levels and overexpression of WNK4 in transgenic
mice leads to FHHt-like phenotypes [81]. This stabilization
of WNKs presumably caused activation of the WNK/
SPAK/OSR1 kinase cascade and hypertension through
excess activity of the WNK/SPAK/NCC pathway. Fur-
thermore, it is unlikely that NCC and SPAK are directly
regulated by CUL3/KLHL3, as neither protein interacts
with KLHL3 [17]. This strongly suggests that the FHHt
phenotype is mediated by a loss of WNK ubiquitylation
and degradation, which can be caused by mutations in
either the ubiquitin E3 or its WNK substrates.
Interestingly, although FHHt patients with mutations in
CUL3, KLHL3 or WNK present the same clinical symp-
toms, those with mutations in CUL3 have a more severe
phenotype, evident in terms of both an earlier age-of-onset
and the degree of hypertension and electrolyte disturbance
reported [15, 84, 85]. So far, all the reported FHHt CUL3
mutations show the deletion of exon 9 in the CUL3 mRNA
Fig. 6 Cartoon to show the
effect of different mutations in
WNKs, KLHL3 or CUL3 on the
docking of WNKs with the
Kelch-like-3/Cullin-3-RING
type E3 ubiquitin ligase
complex. The situation for the
wild-type is shown at top right.
All the mutations ultimately
block WNK ubiquitination, and
hence its degradation by the
proteasome
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which results in the loss of amino acid residues 403–459 in
the protein. These mutations are heterozygous and auto-
somal dominant [15, 84, 85]. Two different mouse models
of CUL3 have been reported, to date. The first is a nephron-
specific deletion of CUL3 that showed the expected
increase in WNK kinase levels as well the phosphorylated
form of NCC [86]. However, the absence of CUL3 lead to
an extended phenotype that is not typical of an FHHt
phenotype. Specifically, the mice showed renal dysfunction
with hypochloremic alkalosis, diabetes insipidus, and salt-
sensitive hypotension. Levels of NKCC2 and AQP2 were
depleted, and the loss of CUL3 leads to a widespread
tubulointerstitial inflammation and fibrosis within the kid-
ney. The second model is a knock-in mouse model for the
exon 9 deletion of CUL3 which exhibited a typical FHHt
phenotype, and the absence of homozygous knock-in mice
for the exon 9 deletion suggested that this mutation is lethal
in utero as a homozygote [16]. The heterozygous animals,
CUL3WT/D403–459 exhibited significantly higher blood
pressure, and an up-regulated WNK kinase pathway similar
to the WNK4 mouse models for FHHt (WNK4 D568E
[87, 88] and KLHL3 R528H [89]). They showed elevated
levels of urine electrolytes with hyperkalemia, hyper-
chloremia and a compensated metabolic acidosis. These
mice had higher aldosterone levels which are more likely
driven by the hyperkalemia. Interestingly, in addition to the
increased absorption of salt through NCC in the DCT, the
CUL3WT/D403–459 mice displayed a thickened aortic wall,
altered aortic pulse pressure waveform and in vivo
responses to pressor agents that together suggested these
mice have an increased contractile state in their vascula-
ture, Thus, the novel vascular phenotype in the CUL3WT/
D403–459 mice, in addition to the hypertension due to salt
retention could possibly explain why FHHt due to CUL3
mutations result in a more severe form of the disease in
comparison to FHHt due to mutations in WNK1, WNK4,
KLHL3.
The vascular phenotype of the CUL3WT/D403–459 mice
may have been anticipated from work done on families
with mutations in the nuclear hormone receptor peroxi-
some proliferator-activated receptor gamma gene (PPARc).
These patients have an intriguing phenotype that includes
lipodystrophy, metabolic syndrome and severe insulin
resistance, but they also have early onset and severe
hypertension [90]. The molecular basis for the hyperten-
sion was studied in a transgenic mouse model [91], which
showed increased RhoA and Rho-kinase (ROCK) activity
in its aorta and an increased contractile state to its of
vascular ex vivo. RhoA protein (the ROCK GTPase regu-
lator) is ubiquitinated and degraded in an analogous
manner to WNKs except that the adaptor/substrate protein
is not KLHL3 but the related adaptor protein RhoBTB1.
This suggested that contraction reflected activation of the
phosphorylation cascade through ROCK that controls
myosin light chain activation in vascular smooth muscle.
Hence, the deletion mutation in Cullin3 would be predicted
to alter the contractile state of blood vessels by reducing
Cullin3-RING ligase activity causing secondary accumu-
lation of RhoA (cf WNKs). This scenario would also
suggest that the abnormal vascular phenotype in FHHt is
restricted to pedigrees with CUL3 but not KLHL3
mutations.
The molecular consequences of the exon 9 deleted form
of mutant Cullin3 have been explored by several groups.
Araki et al. [92] attempted to produce knock-in mouse
models expressing the exon 9 deleted protein by knocking
in two CUL3 human mutations that affect splicing:
G(-1)A/? and 3T(-6)G/T(-6)G [92]. Neither of the
models produced the expected CUL3D403–459 protein, pre-
sumably because of species differences in CUL3 splicing.
Instead, the mutations appeared to behave as null alleles
with the total CUL3WT protein being suppressed by 50
and 25%, respectively. Importantly, neither mouse showed
an FHHt phenotype. The authors reported that no truncated
forms of CUL3 were detected in their mice, although close
inspection of the published western blots (Fig. 4A; Ref
[92]) suggests there were faint bands from a lower MW
form. Of note, the low abundance of the truncated
CUL3D403–459 protein was similarly difficult to demonstrate
in the mouse reported by Schumacher et al. [16]. Hence, it
is possible that splice processing in the models produced by
Araki et al. generated minor truncated forms of CUL3 that
did not mimic either the Schumacher mouse or the human
processing defect.
The exon 9 deleted mutant Cullin3 protein has also been
overexpressed in HEK cells to study its effects. This
appeared to show that it produced reduced RhoA ubiqui-
tination and degradation suggesting a dominant-negative
effect against wild-type Cullin3 protein in vivo [93].
However, the dominant-negative effect observed in HEK
cells may be secondary to marked substrate adaptor protein
depletion. It is also likely that in FHHt patients with
CUL3D403–459 there are very low tissue levels of the exon 9
deleted Cullin3 [16]. Structural modelling combined with
biochemical verifications has also shown that the
CUL3D403–459 mutation provides the Cullin3 protein with
greater flexibility, which probably arises from the exon
deletion splicing together two unstructured regions by
removing three alpha helices. The greater flexibility
impedes its scaffolding function, and prevents the
CUL3D403–459-RING ubiquitin ligase complex from
directing ubiquitin towards the bound substrates, and
instead leads to increased ubiquitination of itself and
Kelch3. In fact, in vivo studies indicate that the
CUL3D403–459 auto-ubiquitinates itself first, as only rela-
tively low amounts of CUL3D403–459 are detectable in
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tissue from the mouse model, while the levels of KLHL3
are unaffected. This auto-degradation of CUL3D403–459
could be a major cause for the associated phenotype in
patients.
Data from in vitro studies [16] show
detectable CUL3D403–459 in cells, but this protein is unable
to ubiquitinate WNK kinases, suggesting that the exon 9
deletion in CUL3 is a loss of function mutation with
respect to substrate ubiquitination. Yet the mutant
CUL3D403–459 protein also failed to inhibit CUL3WT, so it
may not exert a dominant-negative effect in vitro. So how
is the CUL3D403–459 mutation able to produce its effect
in vivo? FHHt patients with the CUL3D403–459 mutation are
heterozygotes, and therefore retain a functional copy of the
gene. This means the CUL3D403–459 mutation either
behaves as a dominant-negative to inhibit CUL3WT or it is
haplo-insufficient with respect to blood pressure regulation,
with a single copy of CUL3 being unable to fulfil its
physiological functions including WNK degradation.
Nevertheless, the work published to date does not resolve
which of these scenarios is correct and more work is
needed.
Blood pressure is maintained by tightly regulated ion
transporters in the epithelia of the distal nephron, which
balance the influx and efflux of salt, and the activities of
these transporters depend on their phosphorylation by
WNK kinases, as discussed in this review. The phospho-
rylation of NCC/NKCC2 by WNK kinases is controlled by
two complementary mechanisms: the regulation of total
WNK protein levels by CUL3–KLHL3, and the level of
WNK activation by phosphorylation. To date, the mecha-
nisms that sense either the need for the phosphorylation of
WNK kinases or their degradation by CUL3–KLHL3 is not
known, or this would be an area for future research.
The discovery of a vascular phenotype in the CUL3WT/
D403–459 mice takes the role of WNK kinases in blood
pressure regulation outside of the kidney. What needs
confirmation is whether this vascular phenotype is a pri-
mary phenomenon or secondary to hypertension driven by
NaCl retention from NCC activation. The CUL3WT/
D403–459 mice have an altered aortic pulse waveform and
slowed diastolic relaxation that is consistent with stiffening
of their arterial tree. An increase in the contractile state of
the vasculature due to wall thickening possibly contributes
to the hypertension in addition to increased salt reabsorp-
tion at the distal nephron in these mice [16]. The WNK1/
WNK3/SPAK/OSR1 pathway is thought to be important
for regulating vascular tone by controlling the phosphory-
lation state of the NKCC1 cotransporter, and hence the
membrane potential of vascular smooth muscle (VSM)
cells [46, 94, 95]. The role of WNK/SPAK kinases in
smooth muscle contraction, and angiogenesis is discussed
in detail in ‘‘WNK/SPAK signalling and vascular smooth
muscle contraction’’ and ‘‘WNK signalling and angiogen-
esis’’ of this review.
Non-kinase dependent effects of WNKs
The WNKs regulate expression of several channels and
transporters that may directly or indirectly impact on the
regulation of blood pressure, e.g. the Cystic Fibrosis
Conductance Regulator (CFTR), renal outer medullary K
channel (ROMK) and the epithelial Na? channel (ENaC).
These effects are generally kinase-independent and cause
altered expression of the target proteins at the cell surface.
They may also operate in tandem with kinase-dependent
effects through WNK/SPAK/OSR1 signalling, although
they have distinct time domains. Hence, in the case of
NCC, altered expression at the cell surface occurs within
15 min of exposure to ATII [96], requires WNK4 and
represents altered trafficking. In contrast, the activation of
NCC by phosphorylation in the same system is only
apparent after 60 min of ATII stimulation and requires
SPAK reflecting WNK/SPAK signalling activation.
In terms of molecular mechanisms, WNK4 reduces
NCC expression at the cell surface by diverting the forward
trafficking of NCC from the trans-golgi network to lyso-
somes. It does this by increasing complex formation with
the adaptor protein AP-3 that is part of a cargo delivery
system moving proteins to the lysosome compartment [97].
This makes use of YXXu recognition motifs present in the
N and C-terminal sequence of NCC. It is unclear to what
extent this mechanism is generalizable to the trafficking of
other WNK targets whose cell surface expression is
affected. Certainly, the interaction of WNKs with CFTR,
ENaC and ROMK channels do not follow this model.
Expression of the CFTR in Xenopus oocytes is reduced
by WNKs with WNK4 reducing channel expression at the
cell surface through a kinase-independent mechanism [98].
However, the effect of WNKs on CFTR expression is
dependent on context as more recent work has highlighted
a kinase called spleen tyrosine kinase (SYK) as having an
important negative regulatory role in modulating CFTR
channel expression [99, 100]. It does this through phos-
phorylation of a single tyrosine residue (Y512) close to the
common mutation site in CFTR (F508). There is cross-talk
between SYK and WNKs with WNK4 sequestering SYK
and preventing Y512 phosphorylation of the CFTR channel
[99]. The alteration of CFTR expression can impact BP and
both cystic fibrosis patients and mice with reduced CFTR
expression have lower BP [101]. It has been speculated that
the prevalence of CF mutations in the population reflects
their protective effect against the development of hyper-
tension. Nevertheless, the exact mechanism for the
hypotensive effect of reduced CFTR expression is not clear
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as the CFTR is widely expressed in transporting epithelia
in the gut, sweat glands, kidney and lung. Recent work in
mice even suggests this may be due to reduced aortic
contractility by affecting calcium mobilization [102].
The ENaC channel is expressed in the distal nephron
where it regulates Na? reabsorption giving the channel a
pivotal role in salt homeostasis and the long-term control of
BP. Expression and activity of ENaC is regulated by the
hormones vasopressin (ADH) and aldosterone. Vasopressin
recycles channels to the cell surface from a recycling pool
[103] while aldosterone drives the synthesis of new ENaC
channels and a kinase, serum-glucocorticoid regulated
kinase 1 (SGK1), that stabilises expression of ENaC at the
cell surface [104–106]. The ENaC channels are normally
cycled from the cell surface after ubiquitination by the
ubiquitin E3 ligase Nedd4-2 and phosphorylation of Ned-
d4-2 by SGK1 reduces its interaction with ENaC [105].
The WNKs interact at several points in this process. First,
WNK1 can bind and activate SGK1, although this is not a
catalytic effect [107] and seems to be common property of
the N-terminal of all four WNKs [108]. WNK4 also
reduces ENaC expression at the cell surface. This effect is
independent of Nedd4-2 so that it is able to reduce surface
expression of ENaC subunits that lack the YY motifs
necessary for interaction with Nedd4-2 [109]. Finally,
WNK4 is itself a substrate for SGK1, although its phos-
phorylation at Ser1169 confers the unusual property of
reversing its action against ENaC [110].
The ROMK channel is expressed only in the kidney. In
the distal nephron, ROMK functions as an important
secretory channel for K?. Since serum K tightly regulates
the synthesis and release of aldosterone ROMK expression
can also modulate BP. It also directly impacts Na?
homeostasis as Na? reabsorption in the thick ascending
limb of the loop of Henle is limited by local K? recycling
through ROMK. The surface expression of ROMK is again
suppressed by WNKs, but the molecular details are distinct
from their effects on ENaC trafficking. Specifically,
ROMK is not internalised by WNKs (WNK1 and WNK4)
through an ubiquitination pathway. Instead, accelerated
internalisation of ROMK is dynamin-dependent and
involves clathrin-coated pits [111, 112].
WNK/SPAK signalling and vascular smooth
muscle contraction
The role of the NKCC1 cotransporter in chloride-trans-
porting epithelia and in the control of cell volume [113] is
well established. Less well appreciated is its role in the
vasculature in controlling blood vessel tone. Although, Cl-
entry into smooth muscle cells generally depolarises the
membrane potential and contracts them [114]. NKCC1 is
the only SLC12A3 sodium-chloride cotransporter expres-
sed in the aorta, and its key role in Cl- entry into vascular
smooth muscle was confirmed by deletion of the trans-
porter in the mouse. The blood pressure in NKCC1-/- mice
was substantially lower than wild-type controls [115].
Electrolyte and aldosterone levels were unaffected in this
model implying that salt and water homeostasis was intact.
However, venous smooth muscle ex vivo showed less tone
and a reduced vasorelaxation to bumetanide. A subsequent
study has shown an effect of NKCC1 inhibition on the
resistance vessels as well [116]. The components of the
WNK/SPAK/OSR1 pathway are present in aortic vascular
smooth muscle and NKCC1 is regulated by phosphoryla-
tion of N-terminal Ser/Thr residues homologous to those
present in the N-terminus of NCC and NKCC2. Confir-
mation of the pathway was provided by a SPAK knockout
mouse that had low blood pressure, reduced aortic phos-
phoNKCC1, and reduced aortic responses to phenylephrine
and bumetanide. The level of phosphoNKCC1 in the aorta
responds directly to dietary levels of salt in the mouse with
a low-salt diet increasing phosphoNKCC1 [95]. This effect
of dietary salt is mimicked by AngII and blocked by the
ATIR receptor antagonist valsartan. Hence the WNK/
SPAK/NKCC1 cascade in vascular smooth muscle appears
to be regulated physiologically by the renin-angiotensin
system.
There is some uncertainty over which various WNK
isoforms is most important in the vessel wall. WNK1
deletion (WNK1-/-) is lethal in utero, but mice with hap-
loinsufficiency for WNK1 (WNK1?/-) have reduced
pressor responses to phenylephrine and reduced contraction
in vitro to a-adrenergic contraction. Isolated vessels also
showed reduced myogenic responses to load [94]. In con-
trast, the WNK/SPAK/NKCC1 cascade was not activated
by ATII or dietary salt restriction in a WNK3 knockout
mouse. This mouse also showed reduced pressor responses
to infused ATII [95]. This suggests that both WNK iso-
forms have a role in the vessel wall with WNK1 perhaps
being more important for catecholaminergic tone and
WNK3 for regulation by the renin–angiotensin system.
WNK signalling and angiogenesis
Mice with homozygous deletion of the WNK1 gene
(WNK1-/-) die in utero before embryonic day 13 [63]. The
development of the heart is abnormal and both sprouting
and remodelling angiogenesis is impaired in WNK1 null
embryos. By crossing Tie2-Cre with floxed WNK1 mice, it
has been shown that it is the endothelial-specific loss of
WNK1 that causes the angiogenesis defects [62]. The
resulting mice are striking for showing ectopic expression
of venous markers in arteries and arterial markers in veins.
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This suggests that WNK1 is acting beyond the differenti-
ation switch that determines whether a nascent vessel
follows an arterial or venous fate. The arterial differentia-
tion switch is dependent on the activation of VEGF/Notch
signalling and the existence of cross-talk between VEGF
and WNK signalling has been suggested by recent work in
Zebrafish [117]. In this model vertebrate species WNK
signalling is again important for the formation of the ves-
sels of the head and trunk. Of note, knock-down of WNK1
with morpholino antisense oligos produced similar defects
in Zebrafish angiogenesis to knock-down of the VEGF2
receptor itself. The VEGFR2 is the major receptor medi-
ating VEGF effects in the vasculature and its Tyrosine
Kinase (TK) function activates downstream kinases
including phosphoinositide-dependent protein kinase (PI3
kinase). PI3 kinase in turn activates another kinase, Akt/
PKB, which is an important kinase in mediating the
metabolic and mitogenic effects of insulin. There is a clear
biochemical opportunity for cross-talk between VEGF and
WNK1 signalling, since the N-terminal of WNK1 has a
phosphorylation consensus sequence for Akt/PKB1, and
IGF-1 stimulates phosphorylation of the conserved Thr60
residue in this sequence in HEK cells [118]. This event
seems to negatively regulate growth, since blockade of
WNK1 phosphorylation increased the effect of insulin on
preadipocyte cell division [119]. The ability of WNK1
mRNA to rescue the effects of VEGF2R knock-down in
Zebrafish also relies on an intact Akt/PKB1 sequence to
allow Thr60 phosphorylation. Akt/PKB1 activation of
WNK1 in the kidney is also seen in db/db mice suggesting
it has a role in the hypertension seen in the metabolic
syndrome [120].
VEGF/WNK signalling and hypertension
Could the interplay of VEGFR2 and WNK1 signalling
pathways have a role in regulating blood pressure outside
of the embryonic vasculature? The widespread use of
inhibitors of VEGF in oncotherapy, both in the form of
monoclonal antibodies to block VEGF receptors or small
molecule inhibitors of VEGF TK receptor signalling has
highlighted a high frequency of hypertension as a side
effect [121]. In trials, the majority of patients actually
develop hypertension especially those involving potent
VEGF TK inhibitors such as axitinib [122]. The severity of
the hypertension parallels the level of functional VEGF
inhibition and is reversed when the inhibitor is stopped.
Hence, an off-target effect seems unlikely and the degree
of hypertension may even be a biomarker of a favourable
treatment response. Nevertheless, the molecular mecha-
nisms behind this pressor effect are still unclear.
Endothelial dysfunction, vascular stiffening or remodelling
and vascular rarefaction (a reduction in the density of
microvessels) have all been suggested [121]. The hypoth-
esis of rarefaction is perhaps the most suggestive of a
mechanism reflecting VEGF/WNK signalling cross-talk.
However, this has not been explored, but is attractive as the
rarefaction may be blocked by drugs targeting the WNK/
SPAK/OSR1 cascade (see ‘‘WNK/SPAK/OSR as a drug-
gable signalling pathway’’).
WNK/SPAK/OSR as a druggable signalling
pathway
The conserved carboxy-terminal (CCT) domain of SPAK
binds with high affinity to RFXV/I motifs that are present
both in its upstream activator (WNKs) as well as its
downstream substrates (Fig. 3). In fact, mutation of a sin-
gle highly conserved Leu502 within the CCT domain
abolishes high affinity binding to the RFXI/V motif. The
critical importance of SPAK docking to its binding partners
for WNK/SPAK/OSR signalling was confirmed by muta-
tion of the canonical Leu50 to alanine [44]. Mice
homozygous for this mutation show marked reduction in
expression and phosphorylation of NCC and NKCC2 in the
kidney. The mice were also hypotensive suggesting that
blocking the CCT domain with a small molecule could
provide a novel antihypertensive strategy.
To identify lead compounds that block binding to the
CCT domain of SPAK, Uchida’s group developed a high-
throughput assay using a fluorescent RFXV/I peptide based
on the motif present in either WNK1 or WNK4 as bate for
a GSK–SPAK–CCT fusion protein [89]. The bait–target
interaction was assessed by fluorescent correlation spec-
troscopy. Using this approach, they were able to identify
ten candidate molecules from a 17,000 compound library
with STOCK1S-50699 (PubChem-CID 5749625) and
STOCK2S-26016 (PubChem-CID 3135086) having the
highest activity. These two molecules were also able to
block phosphorylation of SPAK and NCC in a cell-based
assay. The same group also developed a second high-
throughput assay employing a novel ELISA-based assay to
detect inhibition of NKCC2 phosphorylation [123]. Using
an extended library (totalling almost 22,000 compounds)
they identified a single lead molecule (1S-14279; PubChem
CID 01676700) that in the Biacore system bound to
SPAK with an affinity constant of *105 M-1. Further
work showed that the molecule was chemically similar to
another molecule detected with the assay run against
another smaller targeted library. This molecule was
closantel, a known anthelminthic drug. Both closantel and
1S-14279 appeared to block SPAK docking to it phos-
phorylation target rather than compete with ATP binding.
This is important for specificity of these molecules given
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the structural similarity of the ATP binding site throughout
the family of TK proteins.
In cell-based assays, closantel and 1S-14279 were both
effective at blocking NCC phosphorylation [123]. They
also acutely reduced the level of phosphoNCC and phos-
phoNKCC1 in vivo. However, 1S-14279 appears too toxic
for chronic administration and closantel, while reducing
levels of phosphoproteins very significantly over 7-day
administration had no effect on blood pressure or serum or
urinary electrolytes. However, another very promising lead
molecule has emerged very recently in the form of a sub-
stituted imidazole WNK463 [124]. This compound is able
to block all of the WNKs (WNK1, WNK2, WNK3 and
WNK4) in vitro in the nM concentration range. It is also
orally active and reduced BP, urinary Na? output and
phosphorylation levels of WNK4 in mouse kidney lysates.
However, it has not been developed further as a therapeutic
agent due to problems with its preclinical safety profile.
Nevertheless, WNK463 will be an invaluable tool molecule
and provides a clear proof of principle that targeting the
WNK/SPAK/OSR1 cascade can provide effective antihy-
pertensive drugs for clinical use.
Conclusion
The WNKs are ancient proteins in evolutionary terms and
were co-opted early on to control cell volume and intra-
cellular chloride levels by forming signalling pathways
with the related kinases, SPAK and OSR1. In transporting
epithelium, including the kidney nephron itself these
pathways are crucial to the regulation of ion fluxes by
controlling the phosphorylation state of key membrane
transporters. Hence, the WNK/SPAK/OSR1 signalling
pathway directly influences blood pressure, as is clearly
seen in rare monogenic blood pressure syndromes mutating
single genes in the cascade. Emerging evidence suggests
that WNK/SPAK/OSR1 signalling also operates outside of
the kidney where it is able to regulate blood vessel tone
directly. Much is still to be learned about the physiology
and pathophysiology of the WNKs and their signalling
roles, but targeting the WNK/SPAK/NCC pathway holds
considerable promise for the development of novel anti-
hypertensive drugs and diuretics.
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